FDA 510(k) vs. MDR CE Marking: A Side-by-Side Comparison for Startups

The FDA 510(k) and the MDR CE marking are two different regulatory outcomes produced by two different legal frameworks. A 510(k) is an FDA clearance based on substantial equivalence to a legally marketed predicate device in the United States. A CE mark under Regulation (EU) 2017/745 is a manufacturer's declaration of conformity with the MDR, issued after a Notified Body conformity assessment under Article 52 for most risk classes. Neither recognises the other. For EU startups targeting both markets, the two tracks share some underlying work. QMS, risk management, bench testing, parts of the clinical evidence. But the submissions, the reviewers, the classification logic, and the expected content are distinct and must be planned in parallel from day one.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

• 510(k) and CE marking are not equivalent credentials. A 510(k) is an FDA clearance issued by a US federal agency. A CE mark is a European conformity declaration by the manufacturer, supported by a Notified Body certificate under MDR Article 52 for Class IIa and above.
• Classification does not transfer. MDR classification under Article 51 and Annex VIII follows 22 rules applied by the manufacturer. FDA classification is assigned at the device-type level through FDA classification listings. A device can legitimately land in different classes on the two sides.
• Clinical evidence expectations differ. MDR Article 61 and Annex XIV require clinical evidence for every device. The 510(k) pathway is built on substantial equivalence to a predicate and often does not require new clinical data, though the FDA can request it.
• QMS requirements overlap but are not identical. The EU relies on EN ISO 13485:2016+A11:2021 to support MDR Article 10(9). The US relies on 21 CFR Part 820, which the FDA is bringing into closer alignment with ISO 13485 through its QMSR harmonisation initiative. An ISO 13485 QMS is a strong base for both but does not automatically satisfy Part 820 expectations at the implementation level.
• Timelines and costs differ by pathway and class, not by jurisdiction in a single direction. A clean 510(k) can move faster than an MDR Class IIa conformity assessment. An MDR Class I self-declaration is faster and cheaper than any FDA premarket submission. Neither system is reliably "the fast one."
• Dual-market success is a planning problem, not a translation problem. The work to reuse across tracks is identified at the planning stage, not rediscovered after CE marking is finished.

Why this comparison matters

A German MedTech company Tibor worked with had built a clever device, earned a CE mark, and walked into an investor meeting promising parallel EU and US launches in the same year. When the investor asked how the CE mark helped in the United States, the founder said CE was "international." The meeting ended without a term sheet. The company spent the next months rebuilding its US plan from scratch. New classification analysis, new pathway work, new QMS gap analysis against Part 820, a new clinical evidence review. The CE work was not wasted, but it was not a US submission either. The assumption that CE equals global cost the company a full re-plan, a near-fatal investor relationship, and months of runway.

This is the single most common dual-market mistake Tibor sees. The 510(k) and the CE mark look like two versions of the same thing to a founder seeing them for the first time. They are not. This post puts them next to each other so the differences are visible before they become expensive.

A note on the boundary of our expertise, stated once and clearly: Tibor's authority is the EU MDR and the Notified Body system. He does not hold himself out as an FDA specialist. FDA-specific framing in this post stays at the general level on purpose. Specific CFR provisions, current review division expectations, predicate selection strategy, and submission drafting belong to a US regulatory specialist who practices inside the FDA system daily.

The legal frames are different

Under the MDR, Regulation (EU) 2017/745, a manufacturer places a device on the EU market by demonstrating conformity with the Regulation's requirements and then affixing the CE mark under Article 20. For most devices above Class I, the conformity assessment involves a Notified Body under Article 52, which reviews the quality management system and the technical documentation and issues certificates that support the manufacturer's Declaration of Conformity. The CE mark is not an authorisation issued by a government agency. It is the manufacturer's declaration, backed by Notified Body certification where required.

In the United States, the FDA regulates devices under a federal framework in which the agency itself reviews and clears or approves premarket submissions. The 510(k) is a premarket notification pathway in which the manufacturer demonstrates that the device is substantially equivalent to a legally marketed predicate in terms of intended use and technological characteristics, or that any differences do not raise different questions of safety and effectiveness. The FDA issues a clearance letter. The manufacturer then places the device on the US market under US law.

The consequence is structural. In the EU you build your case and have a Notified Body assess it. In the US you submit your case to the FDA and ask the agency to clear it. One is conformity plus third-party assessment. The other is federal premarket clearance. Neither recognises the other.

Side-by-side: the core comparison table

The table is the orientation. The sections below unpack the dimensions that matter most at planning time.

Device classification: different logics, different outcomes

Under MDR Article 51 and Annex VIII, classification is a rules-based exercise. The manufacturer applies the 22 classification rules to the device's intended purpose and characteristics and arrives at Class I, IIa, IIb, or III. Software is pushed toward higher classes by Annex VIII Rule 11. The rules are uniform across all device types.

On the FDA side, classification is not a rules engine the manufacturer runs. FDA classifications are assigned at the device-type level through FDA-maintained classification listings that map device categories to Class I, II, or III and to specific product codes. The manufacturer's job is to identify the applicable device type in the FDA system, confirm the class and the product code, and then determine which premarket pathway applies. For most Class II devices the pathway is 510(k). For novel devices with no predicate, the De Novo pathway is the correct route. For most Class III devices the pathway is PMA.

The practical consequence for founders is that you cannot assume a mapping. A device that is MDR Class IIa can land in FDA Class II, Class III, or neither if no classification applies yet. This is the first place a US regulatory specialist is worth their fee. The classification and pathway question can usually be answered in a structured meeting once the intended purpose is locked, and getting it wrong ripples through the whole submission plan.

For the MDR side of classification see What Is the EU Medical Device Regulation? A Startup-Friendly Guide. For the comparative overview of the two systems see MDR vs FDA: the core differences every founder should know.

Clinical evidence: two different baselines

MDR Article 61 and Annex XIV require clinical evidence for every device, regardless of class. The level of evidence scales with risk. A Class I surgical instrument and a Class III implantable device do not face the same expectations. But the obligation itself is universal. The Notified Body will assess the clinical evaluation report as part of the technical documentation review.

The 510(k) baseline is different. The pathway is built on substantial equivalence, not on a fresh clinical safety and performance case. For many 510(k) submissions, bench testing, biocompatibility, electrical safety and EMC, software verification, and a well-argued predicate comparison are enough. The FDA retains the right to request clinical data when performance testing is insufficient to answer safety and effectiveness questions, and in specific device categories clinical data is routine. But the default position is not "every device gets clinical investigation."

For EU founders, this can work as an advantage on the US side: MDR clinical evidence often exceeds what a 510(k) needs and can be repurposed as supporting evidence, provided the study was designed with both regulators in mind. The trap is designing a clinical investigation only for MDR Annex XIV endpoints and discovering later that the FDA wants different endpoints or different statistical handling. Plan the clinical strategy once, with both regulators present in the room, not twice in sequence.

QMS: overlapping DNA, different specifics

On the EU side, the MDR requires manufacturers to operate a quality management system under Article 10(9). EN ISO 13485:2016+A11:2021 is the harmonised standard that gives presumption of conformity with those obligations and is the practical baseline every Notified Body expects.

On the US side, the FDA's Quality System Regulation sits at 21 CFR Part 820. The FDA's QMSR harmonisation initiative is moving Part 820 substantively closer to ISO 13485 while preserving US-specific requirements and the FDA's own inspection expectations. The details of the transition and the current timeline should be checked with a US regulatory specialist. The trajectory is well established, but implementation details belong to the specialist's desk.

For startups, the practical rule is: a carefully built ISO 13485 QMS is a strong base for both markets, but it does not automatically satisfy Part 820 at implementation level. A gap analysis between the lean ISO 13485 QMS and Part 820 expectations, done early, turns a painful late discovery into a manageable design decision. For dual-market teams, the Medical Device Single Audit Program (MDSAP) is often the right frame from the start: one QMS audit programme that is recognised by multiple jurisdictions including the US.

For the QMS deep dive see ISO 13485 implementation for MedTech startups and QMS essentials under MDR Article 10.

Timeline: no single winner

Founders often ask which system is faster. The honest answer is that it depends on the pathway, the device, the quality of the submission, and the reviewer on the other side.

A clean 510(k) with a well-chosen predicate can move faster than an MDR Class IIa conformity assessment, particularly given current Notified Body capacity pressure in the EU. An MDR Class I self-declared device can be placed on the market faster than any FDA premarket submission, because there is no premarket review. A PMA-equivalent Class III MDR assessment and an FDA PMA are both long, evidence-heavy processes, and which one takes longer for a specific device is not predictable from the outside.

What is predictable is that both systems reward preparation disproportionately. A rushed 510(k) invites a request for additional information that can add months. A rushed MDR technical documentation invites Notified Body findings that can add a full review cycle. The timeline you can actually plan is the one that starts from a clean, complete, internally consistent submission package. Everything else is a guess.

Cost: the buckets, not the numbers

Cost comparisons between 510(k) and CE marking are misleading when stated as single figures, because the real cost distribution across buckets is different.

On the EU side, the biggest cost buckets are Notified Body fees for conformity assessment and surveillance, internal engineering and regulatory headcount building the technical documentation, clinical evaluation work including any clinical investigation, QMS implementation, and testing. The Notified Body fee is a significant recurring cost because surveillance audits continue through the certificate's life.

On the US side, the biggest buckets are FDA user fees for the submission, US regulatory consulting, performance and bench testing, a US Agent, Part 820 implementation work, and. When required. Clinical data. The FDA user fee for a 510(k) is smaller than a full Notified Body engagement, but the consulting and testing costs for a properly prepared submission are substantial, and for PMA or De Novo the numbers rise sharply.

The right question is not "which is cheaper" but "where do the buckets overlap and where do they not." Testing done once can often serve both submissions. Risk management files built once can serve both. A single QMS can serve both. Clinical evidence designed once with both regulators in mind can often serve both. The dual cost is the sum of the two cost stacks minus the overlaps. And the size of the overlaps depends entirely on how early both markets were in the plan.

Market access scope

A CE mark under MDR gives lawful access to the EU and EEA. It does not give access to the United States, the United Kingdom (post-Brexit UKCA applies), Switzerland (now requiring a separate Authorised Representative arrangement), or any other market that has not recognised it through a specific mechanism.

A 510(k) clearance gives lawful access to the United States. It does not give access to the EU, Canada, Japan, or anywhere else. Each of those jurisdictions has its own framework and its own premarket process.

The rule is simple. Market access is national or supranational. It is never global by default. "International" is a marketing word, not a regulatory status.

What translates across the two tracks, and what does not

What translates, in most cases:

• Risk management work built to ISO 14971:2019+A11:2021. The risk file is reusable across both tracks.
• Bench testing, biocompatibility, electrical safety, EMC, and software verification. Reusable as evidence on both sides, provided the test plans were written with both regulators in mind.
• QMS foundations built to ISO 13485. Reusable with a Part 820 gap close.
• The intended purpose and indications for use. One statement, drafted once, consistent across both submissions.
• Clinical evidence. Partially reusable, depending on study design.

What does not translate:

• The classification outcome.
• The submission itself. The 510(k) and the MDR technical documentation are different documents for different reviewers.
• The clearance or certificate. FDA clearance is not CE, and CE is not FDA clearance.
• Some of the post-market obligations. MDR PMS and PMCF are more structured than the US post-market regime and cannot simply be "copied across."
• The regulatory culture. Communication norms, meeting mechanisms, and interpretation of evidence are not the same on both sides.

The Subtract to Ship angle: dual-market efficiency

The Subtract to Ship framework. Strip every activity that does not trace back to a specific regulatory obligation. Applies cleanly to dual-market work, with one twist. When you are subtracting against two regulations at once, the test is not "does this task have a purpose" but "does this task have a purpose for at least one of the two regulators, and if so, can it be designed once to serve both."

The pattern we see in EU founders who handle US expansion well is not "do less FDA work." It is "do the right work once, early, instead of the wrong work twice, late." The subtraction targets are the false starts: the speculative 510(k) predicate chosen without advice, the QMS rebuilt because a late Part 820 gap surfaced, the clinical investigation re-run because endpoints were MDR-only. These are the activities to remove. The underlying regulatory work. Pathway analysis, QMS alignment, evidence generation, submission drafting. Still has to happen on both sides.

A dual-market Subtract to Ship plan looks like this:

• One intended purpose and indications-for-use statement, drafted once.
• One QMS, built to cover ISO 13485 and Part 820 expectations from day one, MDSAP-ready where the risk class justifies it.
• One risk management file under ISO 14971.
• One clinical evidence plan, designed to satisfy both MDR Annex XIV and FDA expectations where possible.
• Two submissions, prepared in parallel with the appropriate specialists on each side.
• Zero rework caused by planning the tracks in isolation.

See The Subtract to Ship framework for MDR for the foundational methodology that this post applies to the dual-market case.

Reality Check. Are you planning dual-market or wishing for it?

1. Is the United States explicitly in your business plan with a target launch date and a revenue assumption, or is it a "later" item?
2. Do you know the likely FDA device class and product code for your device, or are you assuming it matches your MDR class?
3. Have you confirmed whether a 510(k) predicate exists for your device, or decided that De Novo is the right pathway?
4. Is your intended purpose statement drafted once, consistently, across both regulators?
5. Have you done a gap analysis between your planned ISO 13485 QMS and 21 CFR Part 820 expectations?
6. Is your clinical evidence plan designed to serve both MDR Annex XIV and FDA expectations, or only one of them?
7. Do you have a US regulatory specialist identified, scoped, and budgeted. Not as a future line item but as an active advisor today?
8. If an investor asked you tomorrow how your CE mark helps in the US, would your answer be accurate?

If you cannot answer more than four of these eight clearly, dual-market access is not yet a plan. It is a wish. That is fine if you own it. It is dangerous if you are telling investors otherwise.

Frequently Asked Questions

Is a 510(k) clearance equivalent to a CE mark? No. They are different outcomes from different legal frameworks. A 510(k) is an FDA clearance based on substantial equivalence to a predicate in the United States. A CE mark under MDR is a manufacturer's declaration of conformity with Regulation (EU) 2017/745, supported by a Notified Body certificate under Article 52 for most classes. Neither is recognised by the other system.

Can I reuse my MDR technical documentation for a 510(k)? Partly. Bench testing, biocompatibility, electrical safety, EMC, risk management, and often parts of the clinical evidence can be reused as supporting evidence. The submission itself is different. The 510(k) is organised around substantial equivalence to a predicate, while the MDR technical documentation is organised around conformity with the Regulation. Treat it as shared underlying work feeding two different submissions.

Does an ISO 13485 QMS satisfy the FDA? It is a strong starting point and the FDA's QMSR harmonisation initiative is moving Part 820 closer to ISO 13485. It is not a guaranteed pass. Part 820 has specific requirements and the FDA has its own inspection expectations at the implementation level. Plan for a gap analysis early rather than discovering the gap during an inspection.

Which pathway is faster. 510(k) or CE marking? It depends on the device, the pathway on each side, the quality of the submission, and the reviewer. A clean 510(k) with a strong predicate can move faster than an MDR Class IIa conformity assessment under current Notified Body capacity. An MDR Class I self-declaration is faster than any FDA premarket submission. Neither system is reliably fast. Both reward good preparation disproportionately.

Do I need clinical data for both a 510(k) and a CE mark? For the EU, yes. MDR Article 61 and Annex XIV require clinical evidence for every device, scaled to risk class. For a 510(k), clinical data is often not required because the pathway is built on substantial equivalence to a predicate, though the FDA can request it when performance data is insufficient. For De Novo and PMA on the US side, clinical evidence expectations are significantly higher.

Can I start with CE marking and do FDA later? You can, and many EU startups do, but the timing and the planning matter. Sequential planning. CE first, then start thinking about US. Usually costs more total time than parallel planning, because it forces rework on classification, QMS, clinical design, and intended purpose. The efficient pattern is to plan both from day one and then sequence the execution.

Where does Zechmeister Strategic Solutions sit in a dual-market project? On the EU MDR and Notified Body side. Tibor does not hold himself out as an FDA expert and deliberately keeps this post's FDA framing at the general level. For specific US work. Predicate selection, 510(k) drafting, FDA meeting strategy, Part 820 implementation detail. The right partner is a US regulatory specialist who practices inside the FDA system daily.

Related reading

• MDR vs FDA: the core differences every founder should know – the broader comparative overview.
• Dual-market regulatory strategy for EU startups – the planning companion to this post.
• FDA regulation of medical devices: a primer for EU startups – the parent post in this series.
• FDA device classification for EU startups – the deeper dive into FDA classification logic.
• The 510(k) pathway for EU startups – predicate strategy, submission content, timelines.
• The De Novo pathway for EU startups – when no predicate exists.
• The Subtract to Ship framework for MDR – the foundational methodology.
• MDSAP for startups – one QMS audit, multiple jurisdictions.
• When to start FDA work in an EU-first company – timing the parallel track.

Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (MDR), in particular Article 10 (manufacturer obligations), Article 20 (CE marking), Article 52 (conformity assessment procedures), Article 61 (clinical evaluation), Annex VIII (classification rules), and Annex XIV (clinical evaluation and post-market clinical follow-up). Official Journal L 117, 5.5.2017, as amended, including Regulation (EU) 2023/607.
2. EN ISO 13485:2016 + A11:2021. Medical devices. Quality management systems. Requirements for regulatory purposes.
3. U.S. Food and Drug Administration. Center for Devices and Radiological Health (CDRH), public guidance on device classification and the 510(k) pathway, referenced at the general framework level, https://www.fda.gov/medical-devices
4. U.S. Code of Federal Regulations, Title 21, Part 820. Quality System Regulation for medical devices, with the FDA's Quality Management System Regulation (QMSR) harmonisation initiative, referenced at the general framework level.
5. Medical Device Single Audit Program (MDSAP). Programme documentation maintained by the International Medical Device Regulators Forum (IMDRF).

This post is part of the FDA & International Market Access series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. A note on the limits of our expertise, stated once and clearly: Tibor's authority is in the EU MDR and the Notified Body system, and the FDA framing in this post stays deliberately at the general level. For specific FDA 510(k) questions on your device. Predicate selection, product code and classification lookup, submission drafting, interactions with FDA review divisions, 21 CFR Part 820 implementation detail, and the current state of the QMSR harmonisation timeline. Work with a US regulatory specialist who practices inside the FDA system daily. This post is the orientation. The specialist is the execution.